/
Markets
Crypto
News
Forecasts
Forex Brokers
Calendars
Macro Data
About us
Commodity Prices
Currency Rates
Cryptocurrency Prices
Global Market Indices
Stock Prices
ETF Prices
Cryptocurrency Prices
Crypto Exchanges
Crypto Wallets
Cryptocurrency News
Cryptocurrency Forecasts
Commodity News
Forex News
Crypto News
Stock Market News
Economic News
Opinions
Broker News
Commodities
Forex
Crypto
Indices
Natural Gas Forecasts
Gold Forecasts
WTI Crude Oil Forecasts
S&P 500 Forecasts
Forex Brokers Reviews
Best Brokers Guides
Compare Forex Brokers
Best Forex Brokers
Best Forex Platforms
Best MT4 Brokers
Best for Trading Gold
Best Brokers in Australia
Best Brokers for Beginners
Best Brokers in UK
Brokers Promotions
Stock Brokers
Economic Calendar
Earnings Calendar
Splits Calendar
Dividends Calendar
Holiday Calendar
IPO Calendar
Stock Screener
Currency Converter
Global Macro indicators
Sovereign Credit Ratings
Global Major Indicators
Interest Rates
United States Indicators
China Indicators
Australia Indicators
Euro Area Indicators
About us
Contact Us
Terms Of Use
Become A Contributer
EUR/USD
-0.43%
Natural Gas
+1.82%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
+0.07%
VIX
N/A
Economic Calendar
EUR/USD
-0.43%
Natural Gas
+1.82%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
+0.07%
VIX
N/A
Economic Calendar
BTC
N/A
ETH
N/A
XRP
N/A
ADA
N/A
SOL
N/A
Review
Review
Review
US GDP for Previous Quarter Adjusted Upward to a Robust Annual 3.4%
about 4 hours ago
The Market News Today: US GDP Forecast at 3.2%, Eyes on Fed and Market Response
about 7 hours ago
German Retail Sales Tumble 1.9% in February Driving ECB Rate Cut Bets
about 12 hours ago
Georgia’s Credit Outlook Constrained By Geopolitical Sensitivities, Institutional Risks
1 day ago
Crude Oil Inventories Rise By 3.2 Million Barrels, Exceeding Analyst Expectations
1 day ago
Bank of England FPC Reveals Global Risks and UK Economic Challenges
1 day ago
Natural Gas, WTI Oil, Brent Oil Forecasts – Oil Gains Ground As Traders Bet On Rising Demand
about 1 hour ago
Gold, Silver, Platinum Forecasts – Gold Tests Historic Highs
about 2 hours ago
Is The Pullback In Gold A Perfect Buying Opportunity?
about 3 hours ago
EUR/USD, GBP/USD, USD/CAD, USD/JPY Forecasts – U.S. Dollar Gains Ground As GDP Growth Rate Beats Expectations
about 3 hours ago
Nasdaq 100, Dow Jones, S&P 500 News: Wall Street Eyes Record Highs in Q1, Buoyed by AI Surge, Fed Optimism
about 4 hours ago
Natural Gas Price Forecast – Natural Gas Continues to Sit at Support
about 5 hours ago
Quick Links
:
Forecasts
Economic Calendar
Commodities
Trade Now
ad
ad
Advertisement
Advertisement
home
stocks
BCRX
profile
Biocryst Pharmaceuticals Inc.
Follow
BCRX
(
Nasdaq - US
)
Open
5.16
+0.01 (+0.10%)
in
:
usd
•
As of: Mar 28, 2024 15:11
UTC -4
Open
5.18
High
5.32
Low
5.12
Overview
News & Analysis
Profile
Financials
Advanced Chart
History
Earnings
About
Biocryst Pharmaceuticals Inc.
CEO
Jon P. Stonehouse
Headquarters
4505 emperor boulevard,suite 200
durham, nc 27703, united states
Auditor
Ernst & Young LLP
Employees
536
Share Holders
152
Website
www.biocryst.com
Industry
biotechnology
Sector
health technology
Company Overview
BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.
Biocryst Pharmaceuticals Inc.
Statistics
Valuation Measures
Market Capitalization
2
1.06B
Enterprise Value
1.79B
Enterprise Value/EBITDA
(ttm)
-15.93
Price to Earnings Ratio
(ttm)
N/A
Price to Book
(mrq)
N/A
Price to Sales
(ttm)
3.12
Price to Cash
(ytd)
N/A
Profitability
Gross Margin
(ttm)
98.66%
Operating Margin
(ttm)
-57.98%
Profit Margin
(ttm)
-69.16%
Return on Equity
(ttm)
N/A
Return on Invested Capital
(ttm)
-55.40%
Return on Assets
(ttm)
-36.96%
Income Statement
Revenue
(ttm)
331.41M
Revenue Per Share
(ttm)
1.61
Gross Profit
(ttm)
326.93M
EBITDA
(ttm)
3
-112.32M
Net Income Avi to Common
(ttm)
-226.54M
Diluted EPS
(ttm)
-1.18
Share Statistics
Beta (5Y Monthly)
1.92
52-Week Change
-39.99%
S&P500 52-Week Change
32.36%
S&P500 Member
No
Stock Optionable
Yes
Total Shares Outstanding
1
206.15M
Dividend Yield
0.00%
Float
4
197.08M
%
Held by Insiders
4.40%
%
Held by Institutions
85.88%
Balance Sheet
Total Cash
(mrq)
390.79M
Total Cash Per Share
(mrq)
1.90
Total Debt
(mrq)
839.26M
Total Debt/Equity
(mrq)
-184.24%
Current Ratio
(mrq)
3.31%
Quick Ratio
(mrq)
3.12%
Book Value Per Share
(mrq)
-2.21
Cash Flow
Operating Cash Flow Per Share
(ytd)
-0.49
Free Cash Flow
(ytd)
-97.31M
Table Key
mrq
=
Most Recent Quarter
ttm
=
Trailing Twelve Months
ytd
=
Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.
1
Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2
Market Cap is calculated using total shares outstanding and the most recent share price.
3
EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4
The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Sponsored
Sponsored
This Section / Page contains links to the 3rd party websites of our top partners from whom we may receive compensation.
Trade With A Regulated Broker